Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].
Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF; PROWESS Sepsis Study Group. Kinasewitz GT, et al. Among authors: basson b. Crit Care. 2004 Apr;8(2):R82-90. doi: 10.1186/cc2459. Epub 2004 Feb 10. Crit Care. 2004. PMID: 15025782 Free PMC article. Clinical Trial.
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT; PROWESS Sepsis Study Group. Dhainaut JF, et al. Among authors: basson b. Thromb Haemost. 2003 Oct;90(4):642-53. doi: 10.1160/TH02-11-0270. Thromb Haemost. 2003. PMID: 14515185 Clinical Trial.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators. Angus DC, et al. Among authors: basson br. Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Vincent JL, et al. Crit Care Med. 2003 Mar;31(3):834-40. doi: 10.1097/01.CCM.0000051515.56179.E1. Crit Care Med. 2003. PMID: 12626993 Clinical Trial.
22 results